The 6-Month RR-TB Trial the FDA Should Be Studying as a Pragmatic Design Blueprint

Buried inside the June 25, 2026 issue of the New England Journal of Medicine is a result that the clinical trial design community should be studying as carefully as any infectious disease team: a pragmatic trial of a 6-month treatment strategy for rifampicin-resistant tuberculosis that generated actionable comparative evidence without the infrastructure burden that typically makes high-quality data collection in resource-limited settings impossible. The signal here reaches well beyond tuberculosis.

The trial network behind this result, which includes the endTB consortium (Médecins Sans Frontières, Partners in Health, and Interactive Research and Development), has spent years building pragmatic, embedded trial infrastructure in settings where standard randomized controlled trial machinery collapses under its own weight. What they produced is a design object worth examining: a multi-arm, open-label study enrolling patients with RR-TB across multiple countries, generating comparative efficacy and safety data under conditions of genuine clinical heterogeneity, not the controlled homogeneity that makes Phase 3 results routinely irrelevant to the populations most affected by the disease. The question the rest of the trial design community needs to sit with is whether this model scales beyond infectious disease, and what regulatory systems need to accept before it can.

The stakes are not abstract. The WHO Global Tuberculosis Report 2025 estimates 390,000 new MDR/RR-TB cases annually and 150,000 deaths attributable to drug-resistant TB in 2024 alone. A disease at that scale cannot wait for the 18-month site qualification timelines and 40-page eligibility criteria that characterize conventional Phase 3 development.

The Pragmatic Design Architecture

What separates this trial from the standard RR-TB evidence base is not just the 6-month duration target. The foundational decision was to embed randomization into existing treatment infrastructure rather than erect a parallel clinical research apparatus. Patients were enrolled and managed at facilities already treating RR-TB under national program conditions, with endpoints defined around outcomes that matter to those programs: treatment success at 72 weeks, culture conversion, and adverse event rates that reflect real prescribing patterns rather than protocol-mandated dose modifications.

This approach directly responds to the methodological gap the FDA identified in its draft guidance on Integrating Randomized Controlled Trials into Routine Clinical Practice, which frames the core problem plainly: highly controlled trial environments generate data that regulators can interpret but clinicians cannot use, while real-world practice generates usable data that regulators cannot trust. The endTB pragmatic design attempted to satisfy both constraints simultaneously, and the NEJM publication represents the evidentiary output of that attempt.

The comparison point matters here. The TB-PRACTECAL trial, whose interim results showed 89% treatment success with the BPaLM regimen (bedaquiline, pretomanid, linezolid, moxifloxacin), was conducted under more controlled conditions. Its results were compelling enough to drive WHO’s April 2025 landmark update recommending the all-oral, 6-month BDLLfxC regimen for MDR/RR-TB. But translating that recommendation into operational reality across high-burden, low-resource settings requires pragmatic evidence, not just efficacy signals from controlled environments. The NEJM publication fills precisely that gap.

That gap has regulatory consequences no one has fully resolved.

What Regulators Have Not Said Out Loud

The FDA’s expedited approval of pretomanid in August 2019, part of the BPaL regimen for XDR-TB and treatment-intolerant MDR-TB, was built on limited cohort data from the Nix-TB trial conducted by TB Alliance. The agency accepted that data because the unmet need was catastrophic and the patient population had no alternatives. What the agency has not done is articulate, with any operational precision, how pragmatic trial data from multi-country, program-embedded studies maps onto its regulatory evidence standards for new indications or label modifications.

The WHO took the sharper position. Its April 2025 consolidated TB treatment guidelines restructured the recommendation architecture for MDR/RR-TB based substantially on pragmatic and adaptive evidence sources. That is a normative shift in how an authoritative global health body values evidence generated outside conventional Phase 3 conditions. The FDA has not made a parallel shift, and that asymmetry creates a real operational problem for sponsors and program implementers trying to use pragmatic trial outputs to support regulatory submissions in the United States.

A cost-effectiveness analysis published in 2025 comparing seven short-course DR-TB regimens in India found that all seven short-course options (6 to 9 months) were more cost-effective than the 9- to 11-month standard of care from a health system perspective. That finding applies pressure to health ministries regardless of FDA positioning, but regulatory approval remains the gateway to procurement, reimbursement, and scaled deployment in markets that require it. Pragmatic trial results that drive WHO guidance but cannot easily support an FDA submission represent an evidentiary dead end for global health programs that need both.

Operational Implications for Trial Teams

If you are designing or managing trials in infectious disease, CNS, or any therapeutic area where conventional Phase 3 recruitment fails to reflect the real treatment population, the NEJM RR-TB publication should be on your protocol design team’s reading list before the next design meeting. The specific operational decisions embedded in this trial, including site selection criteria tied to existing treatment capacity, streamlined data collection aligned with national TB program reporting structures, and pre-specified subgroup analyses by fluoroquinolone resistance status, represent a transferable design vocabulary.

The WHO’s July 2021 position statement on innovative clinical trial designs for TB treatment development explicitly endorsed platform trials, multi-arm multi-stage designs, and Bayesian adaptive approaches as acceptable evidence generation frameworks. Any sponsor operating in a high-burden indication with heterogeneous treatment populations should have that document alongside the FDA’s pragmatic trial integration guidance when making protocol architecture decisions. The two documents do not fully align, and that misalignment is where protocol strategy risk lives.

If you are submitting a protocol to a regulatory authority that will require Phase 3-level evidence for a label claim, and your trial is embedded in routine care with the kind of operational flexibility that characterizes the endTB model, you need a pre-submission meeting before your Phase 2 data readout, not after. The FDA’s current framework for integrating pragmatic RCT data into regulatory submissions does not specify how to handle multi-country, program-embedded enrollment where site qualification was determined by treatment capacity rather than GCP infrastructure audit. That ambiguity will be resolved at your expense if you wait for a complete response letter to surface it.

The next signal to watch is whether the FDA issues a formal response or addendum to its pragmatic trial integration guidance that addresses multi-country, resource-limited settings explicitly. The WHO’s April 2025 guideline revision put that question on the table publicly. The FDA’s silence since then has a shelf life, and the NEJM publication of a large-scale pragmatic RR-TB trial result is exactly the kind of evidentiary milestone that typically precedes a regulatory agency’s next guidance cycle. Watch the Federal Register for a notice of proposed rulemaking or a new draft guidance on pragmatic and embedded RCT standards before the end of fiscal year 2027 — and build your protocol flexibility assumptions around what that guidance might require, not what the current framework technically permits.

References

1. New England Journal of Medicine — “A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis” (June 25, 2026)
2. WHO — “WHO Announces Landmark Changes in Treatment of Drug-Resistant Tuberculosis” (April 15, 2025)
3. WHO Global Tuberculosis Report 2025 — Drug-Resistant TB Burden Data
4. CIDRAP — “Trial Results Show Superiority of Shorter All-Oral Treatment for Drug-Resistant TB” (TB-PRACTECAL)
5. CIDRAP — “FDA Approves Pretomanid for Highly Resistant Tuberculosis” (August 2019)
6. FDA — Draft Guidance: “Integrating Randomized Controlled Trials into Routine Clinical Practice”
7. PMC — Cost-Effectiveness Analysis of Short-Course DR-TB Regimens in India (2025)
8. WHO — “Position Statement on Innovative Clinical Trial Designs for Development of New TB Treatments” (July 2021)